Page 35 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective […]

Maurie Markman, MD, discusses current challenges faced with developing robust decision support tools for oncologists and projects additional research efforts dedicated to finding a way to leverage CAR T-cell therapies in solid tumors to improve patient outcomes.

Mizuho started coverage on shares of Kura Oncology (NASDAQ:KURA – Free Report) in a report published on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $26.00 price objective on the stock. Other equities analysts have also issued reports about the stock. Cantor Fitzgerald restated an overweight rating and set a $30.00 […]

Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month […]